BMS, Taris in Bladder Cancer Clinical Trial Pact
By
Bristol-Myers Squibb (BMS) and Taris Biomedical, a Lexington, Massachusetts-headquartered clinical-stage biopharmaceutical company, have entered into a clinical trial collaboration to evaluate the combination of Taris’ investigational product, TAR-200 (GemRIS), in…
Biogen, Ionis Partner for Antisense Oligonucleotide Therapies
By
Biogen and Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, have entered into a collaboration to identify new antisense oligonucleotide drug candidates for treating spinal muscular atrophy (SMA). Biogen will have…
Takeda, Pfizer End Distribution Pact in Japan for Arthritis Drug Xeljanz
By
Pfizer Japan and Takeda Pharmaceutical Company plan to terminate co-promotion of Pfizer’s Xeljanz (tofacitinib citrate) 5-mg tablets, an oral Janus kinase inhibitor for treating rheumatoid arthritis, in Japan, effective March…
BI, Autifony Therapeutics in $742-Million CNS Drug Pact
By
Boehringer Ingelheim (BI) and Autifony Therapeutics, a Verona, Italy-headquartered spin-out from GlaxoSmithKline, have signed an agreement for acquiring certain aspects of Autifony’s voltage-gated potassium channel modulator platform. BI has obtained…